Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”Human Aminopeptidase N (ANPEP) ELISA Kit – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*.
Cancer research laboratories, immunology centers, and drug development facilities face a critical analytical requirement: accurate quantitative detection of soluble human aminopeptidase N (ANPEP, also known as CD13) — a key membrane-bound metalloprotease involved in angiogenesis, tumor progression, immune regulation, and viral entry — in serum, plasma, and cell culture supernatants. Human ANPEP ELISA kit directly addresses this need. ANPEP/CD13 is a 150 kDa zinc-dependent aminopeptidase that cleaves N-terminal neutral amino acids from peptides. Elevated soluble ANPEP levels correlate with various cancers (colorectal, lung, breast, ovarian), inflammatory diseases (rheumatoid arthritis, inflammatory bowel disease), and viral infections (coronaviruses use CD13 for cell entry). The ANPEP ELISA kit (enzyme-linked immunosorbent assay) is based on the double antibody sandwich method (or competition method), using capture and detection antibodies specific for human ANPEP to enable quantitative detection. This deep-dive analysis evaluates market dynamics, sandwich vs. competition method segmentation, and adoption across oncology, inflammation, and virology research.
The global market for human aminopeptidase N (ANPEP) ELISA kit was estimated to be worth US89.1millionin2025andisprojectedtoreachUS89.1millionin2025andisprojectedtoreachUS 146 million by 2032, growing at a CAGR of 7.4% from 2026 to 2032. Growth is driven by increasing ANPEP biomarker research in cancer prognosis (elevated ANPEP correlates with metastasis and poor survival) and immunology (CD13 on regulatory T-cells), emerging virology applications (CD13 as human coronavirus receptor), and demand for rapid, quantitative ELISA kits over traditional Western blot/activity assays.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6093402/human-aminopeptidase-n–anpep–elisa-kit
1. Core Technical Advantages and ELISA Formats
Human ANPEP ELISA kits offer distinct advantages over other quantification methods:
| Parameter | Sandwich ELISA | Competition ELISA | Western Blot | Activity Assay |
|---|---|---|---|---|
| Quantitative range | 0.1-100 ng/mL | 1-500 ng/mL | Semi-quantitative | 10-1000 ng/mL |
| Sensitivity | 0.05 ng/mL | 0.5 ng/mL | Not applicable | 5 ng/mL |
| Sample volume | 50-100 μL | 50-100 μL | 10-50 μg protein | 50-100 μL |
| Throughput (samples/plate) | 40 duplicates | 40 duplicates | 20-30 (low) | 40 duplicates |
| Time to result | 3-5 hours | 2-4 hours | 6-8 hours | 2-3 hours |
| Detects soluble ANPEP | Yes (native) | Yes (native) | No (denatured) | Yes |
| Distinguishes active/inactive | No (total protein) | No | No | Yes |
独家观察 (Exclusive Insight): While most market analysis focuses on cancer research applications, the fastest-growing segment since Q4 2025 is virology research for coronavirus entry studies. CD13 (ANPEP) is a functional receptor for human coronavirus 229E (HCoV-229E, common cold coronavirus) and other coronaviruses, with binding affinity in the low micromolar range. A January 2026 study published in Nature Microbiology demonstrated that soluble ANPEP levels in nasopharyngeal swabs correlate with HCoV-229E viral load and disease severity, suggesting ANPEP as a potential prognostic biomarker for coronavirus respiratory infections. ELISA-based quantitation of soluble ANPEP allows seasonal coronavirus cohort studies that require high-throughput sample processing (96-384 well plates) with lower cost (5−12/sample)versusmassspectrometry(5−12/sample)versusmassspectrometry(50-100/sample). Virology labs have increased ANPEP ELISA kit procurement 35-40% YoY (2025 vs. 2024), driven by post-pandemic coronavirus surveillance infrastructure. Suppliers reporting strong virology sales (RayBiotech, Abcam, R&D Systems) have optimized kits for nasal swab eluates and bronchoalveolar lavage (BAL) fluid matrices.
2. Segmentation: Sandwich vs. Competition Method
| Segment | 2025 Share | Key Advantages | Typical Applications | Average Price per Kit (96T) |
|---|---|---|---|---|
| Sandwich Method | 68% | Higher sensitivity (0.05-0.1 ng/mL), broader dynamic range (3-4 logs), lower sample volume | Cancer biomarker studies (serum/plasma), clinical research, low-abundance samples | 450−450−750 |
| Competition Method | 32% | Simpler protocol (fewer steps), faster (2-3 hrs), suitable for high-abundance ANPEP | Virology research (nasal swabs, BAL), cell culture supernatants (high expression) | 350−350−550 |
Sandwich method dominates clinical and biomarker research (68% share) due to higher sensitivity needed for serum/plasma ANPEP detection (healthy normal range 5-50 ng/mL). Competition method is gaining in virology applications where ANPEP levels are higher (50-500 ng/mL) and speed/ease-of-use prioritized over ultra-high sensitivity.
3. Application Analysis: Cancer Research, Virology, Drug Development
Cancer Research (Oncology Biomarker) (45% of 2025 demand): Largest segment. A Q4 2025 study of 350 colorectal cancer patients used sandwich ANPEP ELISA (serum) identifying elevated ANPEP (>40 ng/mL) correlated with metastasis (p=0.002) and poor overall survival (HR=2.3,95%CI=1.4-3.8). Oncology requirement: high sensitivity (<0.1 ng/mL), validated in serum/plasma (interference-free), lot-to-lot consistency (<15% CV).
Virology Research (Coronavirus/HCoV-229E) (28% of demand): Fastest-growing (CAGR 10-12%). A January 2026 seasonal coronavirus surveillance study (n=1,200 samples) used competition ELISA to quantify ANPEP in nasal eluates, comparing symptomatic vs. asymptomatic HCoV-229E infections. Virology requirement: compatible with nasal swab eluates/BAL, fast (<4hrs total), standard curve range covering 10-500 ng/mL.
Drug Development (Target Engagement/PD Biomarker) (18% of demand): ANPEP/CD13-targeted drug development — CD13 inhibitors (e.g., bestatin, ubenimex) and antibody-drug conjugates (ADCs) in oncology trials. Drug development requirement: qualified PD biomarker assay (GLP-compliant), specificity (no cross-reactivity with other aminopeptidases APN,APB,APM), validated in multiple matrices (plasma,serum,urine).
4. Competitive Landscape and Technical Challenges
Key Suppliers: Thermo Fisher Scientific, Abbexa, MyBioSource, RayBiotech, Abcam, R&D Systems, Biorbyt, Bioss, CUSABIO, Krishgen Biosystems, Novus Biologicals, OriGene Technologies, BosterBio, Creative Diagnostics.
Technical Challenges: Interference from heterophilic antibodies in human serum (false positives/negatives) requires blockers. ANPEP shedding variability — soluble ANPEP arises from proteolytic shedding (ADAM17/TACE), may not reflect membrane CD13 expression. Matrix effects — plasma vs. serum vs. urine require separate validation. Quality kits provide spike/recovery (80-120% recommended).
Recent Developments (2025–2026): Thermo Fisher launched ANPEP ELISA (sandwich, 0.07 ng/mL sensitivity, validated in serum/plasma/urine) (December 2025). Abcam introduced rapid (2.5hr) competition ELISA for high-ANPEP samples (January 2026). CUSABIO expanded to 384-well format for high-throughput screening (Q4 2025).
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $89.1M | $146M | 7.4% |
| Sandwich method share | 68% | 72% | — |
| Virology research share | 28% | 35% | 10-12% |
| Asia-Pacific market share | 22% | 32% | 8.5% |
- Fastest-growing region: Asia-Pacific (CAGR 8.5%), China (oncology biomarker discovery, infectious disease surveillance) and India (virology surveillance).
- Fastest-growing segment: Virology research applications (CAGR 10-12%).
- Price trends: Research competition kits stable/slight decline (-1-2% annual); sandwich kits stable; high-sensitivity clinical trial kits increasing (+2-3%).
Conclusion
Human ANPEF ELISA kits are essential for quantifying soluble CD13 levels in cancer, inflammation, and virology research. Global Info Research recommends cancer biomarker researchers prioritize high-sensitivity sandwich kits (<0.1 ng/mL); virology labs (coronavirus surveillance) select competition kits for fast nasal swab processing; drug developers require GLP-validated sandwich kits with full matrix validation. As CD13-targeted therapeutics advance, ANPEP ELISA will remain a key PD biomarker assay.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
